n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)
Santarus' CEO Hosts Business Update Conference Call (Transcript)

Santarus' CEO Hosts Business Update Conference Call (Transcript)

Santarus' CEO Hosts Business Update Conference Call (Transcript)

Santarus Adds FENOGLIDE To Marketed Products Portfolio

Santarus Adds FENOGLIDE To Marketed Products Portfolio

Santarus, Inc. (NASDAQ: SNTS) today announced that it has entered into an exclusive license agreement with Shore Therapeutics, Inc.

Santarus Submits New Drug Application To FDA For UCERIS (budesonide) Tablets

Santarus Submits New Drug Application To FDA For UCERIS (budesonide) Tablets

Santarus, Inc. (NASDAQ: SNTS) today announced that it has submitted a New Drug Application (NDA) to the U.

Santarus And Pharming Announce Oral Presentations Of Retrospective Analyses Of Data From RHUCIN Clinical Program At World Allergy Congress

Santarus And Pharming Announce Oral Presentations Of Retrospective Analyses Of Data From RHUCIN Clinical Program At World Allergy Congress

Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced that retrospective analyses of integrated efficacy data and immuno-safety data were presented in two oral presentations at the...

Santarus' CEO Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Event Transcript

Santarus' CEO Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Event Transcript

Santarus' CEO Presents at Lazard Capital Markets 8th Annual Healthcare Conference - Event Transcript

Santarus' CEO Discusses At Lazard Capital Markets 8th Annual Healthcare - Conference Call Transcript

Santarus' CEO Discusses At Lazard Capital Markets 8th Annual Healthcare - Conference Call Transcript

Santarus' CEO Discusses at Lazard Capital Markets 8th Annual Healthcare - Conference Call Transcript

Santarus Announces Presentation Of New Open-Label UCERIS (Budesonide) Data At The Crohn’s And Colitis Foundation Clinical & Research Conference

Santarus Announces Presentation Of New Open-Label UCERIS (Budesonide) Data At The Crohn’s And Colitis Foundation Clinical & Research Conference

Santarus, Inc. (NASDAQ: SNTS) today announced that new data from a clinical study to assess the efficacy and safety of eight weeks of open-label treatment with the investigational drug UCERIS ™ (budesonide) ...

Santarus Inc. Stock Upgraded (SNTS)

Santarus Inc. Stock Upgraded (SNTS)

Santarus (Nasdaq:SNTS) has been upgraded by TheStreet Ratings from a sell to hold.

Santarus To Present At November Investment Conferences

Santarus To Present At November Investment Conferences

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Santarus' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Santarus' CEO Discusses Q3 2011 Results - Earnings Call Transcript

Santarus Reports Third Quarter 2011 Financial Results

Santarus Reports Third Quarter 2011 Financial Results

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2011.

Santarus And Pharming Announce Presentation Of Retrospective Analyses Of Data From Clinical Studies Of RHUCIN

Santarus And Pharming Announce Presentation Of Retrospective Analyses Of Data From Clinical Studies Of RHUCIN

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that a retrospective analysis of integrated efficacy data from patients...

Santarus Announces Presentation Of Pooled Data From Budesonide MMX Phase III Clinical Studies At The ACG Annual Scientific Meeting

Santarus Announces Presentation Of Pooled Data From Budesonide MMX Phase III Clinical Studies At The ACG Annual Scientific Meeting

Santarus, Inc. (NASDAQ:SNTS) today announced the presentation of an analysis of pooled data from its two Phase III clinical studies indicating that the investigational drug budesonide MMX ® 9 mg taken once ...

Santarus To Hold Third Quarter 2011 Financial Results Conference Call On November 7

Santarus To Hold Third Quarter 2011 Financial Results Conference Call On November 7

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release third quarter 2011 financial results after market close on Monday, November 7, 2011.

Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript

Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript

Santarus' CEO Discusses UBS Global Life Sciences Conference Call Transcript

Santarus Announces Supportive Top-Line Results From Budesonide MMX Extended Use Study

Santarus Announces Supportive Top-Line Results From Budesonide MMX Extended Use Study

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with...

Santarus To Present At September Investment Conferences

Santarus To Present At September Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products

Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products

Santarus, Inc. (NASDAQ:SNTS) and Depomed, Inc.

Santarus To Present At The 2011 Wedbush Life Sciences: Management Access Conference

Santarus To Present At The 2011 Wedbush Life Sciences: Management Access Conference

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Pharming Announce Special Protocol Assessment (SPA) Agreement With FDA For RHUCIN Phase III Clinical Study

Santarus And Pharming Announce Special Protocol Assessment (SPA) Agreement With FDA For RHUCIN Phase III Clinical Study

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that they have reached agreement with the U.

Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q2 2011 Results - Earnings Call Transcript

Santarus Reports Second Quarter 2011 Financial Results

Santarus Reports Second Quarter 2011 Financial Results

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2011.

Santarus To Hold Second Quarter 2011 Financial Results Conference Call On August 3

Santarus To Hold Second Quarter 2011 Financial Results Conference Call On August 3

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it will release second quarter 2011 financial results after market close on Wednesday, August 3, 2011.

Santarus Appoints Wendell Wierenga Executive Vice President, Research And Development

Santarus Appoints Wendell Wierenga Executive Vice President, Research And Development

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, announces that Wendell Wierenga, Ph.

Santarus To Present At The Wells Fargo Securities 2011 Healthcare Conference

Santarus To Present At The Wells Fargo Securities 2011 Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus Announces Presentation Of RHUCIN Clinical Data At 7th C1 Inhibitor Deficiency Workshop

Santarus Announces Presentation Of RHUCIN Clinical Data At 7th C1 Inhibitor Deficiency Workshop

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN ® (recombinant...

Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript

Santarus CEO Discusses Q1 2011 Results - Earnings Call Transcript

Santarus Reports First Quarter 2011 Financial Results

Santarus Reports First Quarter 2011 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2011.

Santarus Announces Oral Presentations Of Budesonide MMX Phase III Data At Digestive Disease Week Meeting

Santarus Announces Oral Presentations Of Budesonide MMX Phase III Data At Digestive Disease Week Meeting

Santarus, Inc. (NASDAQ: SNTS) today announced that the budesonide MMX ® Phase III clinical program will be featured in two oral presentations at the Digestive Disease Week (DDW) Meeting being held at McCormick Place ...

Santarus To Hold First Quarter 2011 Financial Results Conference Call On May 4

Santarus To Hold First Quarter 2011 Financial Results Conference Call On May 4

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release first quarter 2011 financial results after market close on Wednesday, May 4, 2011.